Jeff Aronin receives Northern Illinois University’s 2019 Innovation and Entrepreneurship Award, presented by Dr. Lisa Freeman, President of NIU, and Dr. Balaji Rajagopalan, Dean of the College of Business. Chicago, IL, May 13, 2019 – Paragon Biosciences, LLC Chairman and CEO Jeff Aronin was recently recognized by the Northern Illinois University (NIU) College of [...]
The newly-created position is the result of rapid expansion at Paragon and its portfolio companies, which are developing novel medical treatments Chicago, IL, April 22, 2019 – Paragon Biosciences, LLC announced today the appointment of James (Jim) Robinson to the role of President and Chief Operating Officer, effective April 22. Reporting directly to Paragon Chairman [...]
With its highest honor, a Gold level award, Best in Biz recognizes Jeff Aronin for his lifelong commitment to developing breakthrough therapies for severe medical conditions. December 3, 2018 – Paragon Biosciences Chairman and CEO Jeff Aronin was named 2018’s Innovator of the Year, by Best in Biz Awards, for his lifelong commitment to developing [...]
Paragon organizes new investment from Fidelity Management & Research Company and Valor Equity Partners for portfolio company Castle Creek Pharma CHICAGO, IL – October 19, 2018 – Paragon Biosciences (Paragon) today announced the completion of a new capital investment of $71.8 million for Castle Creek Pharma (Castle Creek), a Paragon portfolio company. Paragon builds innovative [...]
October 19, 2019 – Paragon Biosciences CEO Jeff Aronin spoke with Crain’s Chicago Business on his role in the company, his vision for Paragon, and his mission to bring treatments to patients suffering from rare, genetic, debilitating diseases that too few companies focus on. In an exclusive interview, Jeff shared Paragon’s announcement on the completion of a [...]
Paragon CEO Jeff Aronin Recognized by Insights Care Magazine as “Innovative Entrepreneur Putting Patients First” October 1, 2018 – Paragon Biosciences CEO Jeff Aronin was recognized this week by Insights Care magazine for his innovative leadership in the biosciences sector and for his work bringing life-altering drugs to patients in need. Jeff’s vision has led Paragon [...]
CHICAGO – August 21, 2018 – Paragon Biosciences (Paragon) today announced Skyline Biosciences (Skyline) as the newest addition to its growing portfolio of drug-development companies. Paragon identifies unmet patient needs, invests in the development of novel medicines, and incubates biopharmaceutical companies, such as Skyline. “Skyline is working on promising therapies to treat oral precancerous lesions,” said [...]
CHICAGO – August 14, 2018 – Biopharmaceutical company Emalex Biosciences (Emalex), the newest member of the Paragon Biosciences (Paragon) portfolio of companies, today announced it acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register and market ecopipam, a new chemical entity with orphan drug designation for the treatment of pediatric Tourette Syndrome (TS) in patients [...]
Biopharmaceutical company currently evaluating diacerein 1% ointment (CCP-020) in ongoing DELIVERS study PARSIPPANY, NJ – August 9, 2018 – Castle Creek Pharmaceuticals, LLC., a US-based company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the U.S. Food & Drug Administration (FDA) has designated as a Fast [...]
New multi-center Phase 1 study expected to enroll up to 20 people living with rare genetic condition that leads to extremely fragile skin PARSIPPANY, NJ – June 25, 2018 – Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the [...]
© 2022 Paragon Biosciences LLC | Privacy Policy | Terms of Use
